BMGL · Basel Medical Group Ltd
Market Cap
$6.50M
Shares
1.58M
Volume · Oct 20
1.35M
Avg daily vol (3M)
714.78K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.18
Open$4.08
Day$4.03–4.29
52W close$3.02–19.92
Avg vol 30d1.4M
Short int11K · 0.7% float · 1.0d
Short vol65%
DataFeb 2025–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$11.14M
Trailing 12 months
Net income (TTM)
−$7.69M
Trailing 12 months
Revenue growth YoY
+12.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-31.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.7%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−37%
below
Price vs 50-day avg
−7%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
7%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−44%
trailing
YTD return
−29%
this year
Relative strength
−52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
1 of 2 funds reported for Sep 30 · net +1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.71% of float · ▼ -92.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2 holders — mid 1-yr range
Squeeze score
28
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
132%
annualized · 1-yr
Max drawdown
−85%
past year
ATR
12.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−37%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
7%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
1 of 2 funds reported for Sep 30 · net +1 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.71% of float · ▼ -92.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
2 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $3
Now $4 · 7%
Range high $20
vs 200-day avg -37%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMGL
this stock
Basel Medical Group Ltd
|
$6.50M | — | — | — | 0.7% |
|
HCA
HCA Healthcare, Inc.
|
$103.32B | -0.2% | +7.1% | 15.6 | 2.2% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.30B | -11.7% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.45B | +37.0% | +0.9% | 10.3 | 2.3% |
|
EHC
Encompass Health Corp
|
$12.00B | +14.6% | +10.5% | 19.8 | 3.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
3
- % held
- 0.0%
- Reported
- 1 of 2
- Top holder
- UBS Group AG
Held
Float
Short & Settlement
Filings
SEC Filings
Latest
6-K
- Filed
- Oct 13, 2026
- This year
- 15
Basel Medical Group Ltd closed an offering on October 9, 2026, issuing 6,000,000 units and 6,000,000 Common Warrants exercisable at US$1.463 per Ordinary Share. Gross proceeds were US$7.98 million, with estimated net proceeds of approximately US$7.28 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMGL | +8.6% | -0.2% | -43.8% | +34.0% | -28.9% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +9.7% | +0.3% | -51.9% | +33.1% | -41.7% |